TrialLancet (London, England)2020

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.

Feng-Cai Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.